|
WO2014189646A1
|
|
Processes and intermediates useful for preparing cysteine protease inhibitors
|
|
WO2014153113A2
|
|
Processes and intermediates for the preparation of 3 amino-n-cyclopropyl-2 hydroxypropionamide derivatives
|
|
US2014256698A1
|
|
Cathepsin inhibitors
|
|
CN104039151A
|
|
Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
|
|
WO2009114633A1
|
|
Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
|
|
BRPI0907729A2
|
|
Methods for treating cathepsin b-mediated diseases in a mammal and for treating an individual diagnosed with both hcv and fribose in a mammal
|
|
EP2215076A2
|
|
Compounds that inhibit protease cathepsin s and hcv replication
|
|
WO2009039361A2
|
|
Process for the preparation of (s)-2-(3-tert-butylureido)-3,3-dimethylbutanoic acid
|
|
WO2009123623A1
|
|
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
US2008293819A1
|
|
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
WO2008086053A1
|
|
Hcv inhibitors
|
|
NZ576105A
|
|
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
US2007287699A1
|
|
Antiviral agents
|
|
TW200744625A
|
|
Hcv inhibitors
|
|
WO2007005779A2
|
|
Antiviral agents
|
|
US2007054864A1
|
|
HCV inhibitors
|
|
NZ561681A
|
|
Alpha ketoamide compounds as cysteine protease inhibitors
|
|
EP1819667A1
|
|
Sulfonamide compounds as cysteine protease inhibitors
|
|
US2005182096A1
|
|
Haloalkyl containing compounds as cysteine protease inhibitors
|
|
US2006264464A1
|
|
Amidino compounds as cysteine protease inhibitors
|
